scholarly journals Peptide-Modulated Activity Enhancement of Acidic Protease Cathepsin E at Neutral pH

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Masayuki Komatsu ◽  
Madhu Biyani ◽  
Sunita Ghimire Gautam ◽  
Koichi Nishigaki

Enzymes are regulated by their activation and inhibition. Enzyme activators can often be effective tools for scientific and medical purposes, although they are more difficult to obtain than inhibitors. Here, using the paired peptide method, we report on protease-cathepsin-E-activating peptides that are obtained at neutral pH. These selected peptides also underwent molecular evolution, after which their cathepsin E activation capability improved. Thus, the activators we obtained could enhance cathepsin-E-induced cancer cell apoptosis, which indicated their potential as cancer drug precursors.

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yu Wang ◽  
Liming Zhu ◽  
Mei Guo ◽  
Gang Sun ◽  
Kun Zhou ◽  
...  

AbstractWHSC1 is a histone methyltransferase that facilitates histone H3 lysine 36 dimethylation (H3K36me2), which is a permissive mark associated with active transcription. In this study, we revealed how WHSC1 regulates tumorigenesis and chemosensitivity of colorectal cancer (CRC). Our data showed that WHSC1 as well as H3K36me2 were highly expressed in clinical CRC samples, and high WHSC1 expression is associated with poorer prognosis in CRC patients. WHSC1 reduction promoted colon cancer cell apoptosis both in vivo and in vitro. We found that B cell lymphoma-2 (BCL2) expression, an anti-apoptotic protein, is markedly decreased in after WHSC1 depletion. Mechanistic characterization indicated that WHSC1 directly binds to the promoter region of BCL2 gene and regulate its H3K36 dimethylation level. What’s more, our study indicated that WHSC1 depletion promotes chemosensitivity in CRC cells. Together, our results suggested that WHSC1 and H3K36me2 modification might be optimal therapeutic targets to disrupt CRC progression and WHSC1-targeted therapy might potentially overcome the resistance of chemotherapeutic agents.


2020 ◽  
Vol 21 (10) ◽  
pp. 571-582
Author(s):  
Jia Qi Li ◽  
Jia Lu Li ◽  
Yuan Hong Xie ◽  
Yao Wang ◽  
Xiao Nan Shen ◽  
...  

2020 ◽  
Vol 11 (4) ◽  
Author(s):  
Qixing Tan ◽  
Shuxian Zou ◽  
Rui Jin ◽  
Yongliang Hu ◽  
Huan Xu ◽  
...  

2015 ◽  
Vol 10 (6) ◽  
pp. 3434-3442 ◽  
Author(s):  
DAN LU ◽  
JING QIAN ◽  
WEI LI ◽  
QIANQIAN FENG ◽  
SHU PAN ◽  
...  

Oncogene ◽  
2015 ◽  
Vol 34 (49) ◽  
pp. 5983-5996 ◽  
Author(s):  
S Ohno ◽  
Y Naito ◽  
S Mukai ◽  
N Yabuta ◽  
H Nojima

Sign in / Sign up

Export Citation Format

Share Document